These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12540598)

  • 1. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
    Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
    Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
    Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
    Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
    Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
    Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
    Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
    Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
    Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
    Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
    Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
    Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
    Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
    Carey DG; Cowin GJ; Galloway GJ; Jones NP; Richards JC; Biswas N; Doddrell DM
    Obes Res; 2002 Oct; 10(10):1008-15. PubMed ID: 12376581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
    van Wijk JP; de Koning EJ; Cabezas MC; op't Roodt J; Joven J; Rabelink TJ; Hoepelman AI
    Ann Intern Med; 2005 Sep; 143(5):337-46. PubMed ID: 16144892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.
    Gelato MC; Mynarcik DC; Quick JL; Steigbigel RT; Fuhrer J; Brathwaite CE; Brebbia JS; Wax MR; McNurlan MA
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):163-70. PubMed ID: 12394794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans.
    Virtanen KA; Lönnroth P; Parkkola R; Peltoniemi P; Asola M; Viljanen T; Tolvanen T; Knuuti J; Rönnemaa T; Huupponen R; Nuutila P
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3902-10. PubMed ID: 12161530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
    Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
    Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
    AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
    Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
    Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.